Key Takeaways
- • Sam Altman's venture capital firm Hydrazine Capital closed its fourth fund in March 2023 with a $75 million commitment from the University of Michigan's $17.9 billion endowment, representing the second investment the university has made into Altman's venture platform.
- • The University of Michigan endowment is a multi-stage investor in Altman's ecosystem, having committed capital not only to Hydrazine Capital but also directly to OpenAI and OpenAI's corporate venture fund, signaling confidence in Altman's AI-focused investment thesis.
- • Hydrazine IV is structured as a small fund with the University of Michigan serving as the sole outside institutional investor, distinguishing it from typical venture capital fundraising models and suggesting a specialized or relationship-driven investment strategy.
- • The investment was disclosed through Freedom of Information Act filings obtained by Fortune and represents the first public confirmation that Altman's personal venture firm deploys institutional capital beyond his own capital and personal networks.
- • OpenAI stated that Altman "spends only a small fraction of his time investing" despite managing a venture capital fund during his tenure as CEO of one of the technology industry's most prominent AI companies.
Summary
Sam Altman, CEO of OpenAI, quietly secured a $75 million commitment from the University of Michigan's endowment for Hydrazine Capital's fourth fund, which launched in March 2023. The commitment was made sometime before the end of June 2023, marking the second investment the University of Michigan endowment has directed toward Altman's venture capital platform. Fortune discovered the investment through public filings and documents obtained via Freedom of Information Act request.
The University of Michigan's $17.9 billion endowment has established itself as a multi-layer investor in Altman's AI ecosystem. Beyond the Hydrazine Capital commitment, the endowment has made direct investments in OpenAI itself and in OpenAI's corporate venture fund. Dan Feder, senior managing director of investments at the university's endowment, characterized the relationship as longstanding, stating: "Hydrazine IV is a small fund in which the University of Michigan is the only outside investor, and this is an extension of our ongoing investment strategies."
The disclosure carries significance on two fronts. First, it provides the first public confirmation that Altman's personal venture firm manages institutional capital beyond his own funds or those of close associates. Second, it demonstrates that the CEO of one of Silicon Valley's most prominent artificial intelligence companies has been actively fundraising and managing a separate venture portfolio concurrent with his primary role at OpenAI.
The exact size and investment focus of Hydrazine IV remain undisclosed. Feder, OpenAI, Altman, and Hydrazine all declined to provide additional details regarding the fund's strategy or portfolio composition. In response to inquiries, OpenAI's communications team issued a statement asserting that Altman "is fully focused on his role as CEO of OpenAI and spends only a small fraction of his time investing," addressing potential concerns about competing commitments between his roles as both CEO and venture capitalist.
The University of Michigan's $17.9 billion endowment has established itself as a multi-layer investor in Altman's AI ecosystem. Beyond the Hydrazine Capital commitment, the endowment has made direct investments in OpenAI itself and in OpenAI's corporate venture fund. Dan Feder, senior managing director of investments at the university's endowment, characterized the relationship as longstanding, stating: "Hydrazine IV is a small fund in which the University of Michigan is the only outside investor, and this is an extension of our ongoing investment strategies."
The disclosure carries significance on two fronts. First, it provides the first public confirmation that Altman's personal venture firm manages institutional capital beyond his own funds or those of close associates. Second, it demonstrates that the CEO of one of Silicon Valley's most prominent artificial intelligence companies has been actively fundraising and managing a separate venture portfolio concurrent with his primary role at OpenAI.
The exact size and investment focus of Hydrazine IV remain undisclosed. Feder, OpenAI, Altman, and Hydrazine all declined to provide additional details regarding the fund's strategy or portfolio composition. In response to inquiries, OpenAI's communications team issued a statement asserting that Altman "is fully focused on his role as CEO of OpenAI and spends only a small fraction of his time investing," addressing potential concerns about competing commitments between his roles as both CEO and venture capitalist.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.